Spero Therapeutics (SPRO) Accumulated Expenses (2016 - 2026)

Spero Therapeutics has reported Accumulated Expenses for 11 years, with the latest figure at $575000.0 in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 88.21% year-over-year to $575000.0; the trailing twelve-month figure through Mar 2026 stood at $575000.0 (down 88.21% YoY), and the FY2025 full-year result was $5.6 million, down 68.53% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $575000.0, down from $5.6 million in the prior quarter.
• The five-year high for Accumulated Expenses was $17.7 million in Q4 2024, with the low at $575000.0 in Q1 2026.
• Historically, Accumulated Expenses has averaged $7.0 million across 5 years, with a median of $6.6 million in 2023.
• Annual changes were most pronounced in 2023 — Accumulated Expenses surged 269.71% — and 2026, when it sank 88.21%.
• Spero Therapeutics' Accumulated Expenses stood at $9.0 million in 2022, then dropped by 26.93% to $6.6 million in 2023, then soared by 170.31% to $17.7 million in 2024, then tumbled by 68.53% to $5.6 million in 2025, then slumped by 89.69% to $575000.0 in 2026.
• The last three Accumulated Expenses figures came in at $575000.0 (Q1 2026), $5.6 million (Q4 2025), and $7.8 million (Q3 2025), per Business Quant data.